RESPONSE OF CANINE SOFT-TISSUE SARCOMAS TO RADIATION OR RADIATION PLUS HYPERTHERMIA - A RANDOMIZED PHASE-II STUDY

被引:48
|
作者
GILLETTE, SM
DEWHIRST, MW
GILLETTE, EL
THRALL, DE
PAGE, RL
POWERS, BE
WITHROW, SJ
ROSNER, G
WONG, C
SIM, DA
机构
[1] COLORADO STATE UNIV,DEPT RADIOL & RADIAT BIOL,FT COLLINS,CO 80523
[2] COLORADO STATE UNIV,DEPT CLIN SCI,FT COLLINS,CO 80523
[3] DUKE UNIV,MED CTR,DIV RADIAT ONCOL,DURHAM,NC 27710
[4] N CAROLINA STATE UNIV,COLL VET MED,RALEIGH,NC
[5] JOHN P ROBARTS RES INST,CLIN TRIALS RES GRP,LONDON N6A 5KB,ONTARIO,CANADA
关键词
HYPERTHERMIA; RADIATION; CANINE SARCOMAS;
D O I
10.3109/02656739209021786
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Sixty-four dogs with spontaneous soft tissue sarcomas without evidence of metastases were stratified by tumour volume and randomized to receive graded doses of radiotherapy (XRT) alone or radiotherapy plus hyperthermia (HT). An improvement in duration of local control was achieved with the addition of hyperthermia as compared with XRT alone (Wilcoxon, p = 0.040; log rank, p = 0.064). Overall frequency of late complications was not different for the two treatment arms when comparing across equivalent XRT dose groups. Frequency of distant metastases after therapy completion was not significantly different for the two treatment arms at 1 year (7.4% for XRT versus 20% for HT plus XRT) or 2 years (11.5% for XRT versus 25% tor HT plus XRT) post therapy. These results suggest that a therapeutic gain was achieved for this group of tumour-bearing animals. Uni- and multivariate analyses were performed to examine the potential for various factors to influence treatment outcome. Patient related variables included tumour stage. histologic subtype and grade and tumour site. Treatment related variables included total radiation dose and 15 descriptors of temperature distributions achieved during hyperthermia. When considering patient related factors, tumour histology, grade and location were important predictors of time to minimum volume, but only tumour location influenced time to tumour regrowth. When considering treatment related factors, radiation dose was not significantly correlated with time to minimum volume or time to local regrowth, but it was correlated with probability for late normal tissue damage in the XRT alone group (p = 0.005). For the hyperthermia treatments, 13 of 15 tumour temperature distribution descriptors were correlated with time to minimum volume, but none were correlated with time to local regrowth. These results suggest that caution should be used in interpreting the value of temperature distribution descriptors in predicting for long-term local control after hyperthermia and radiotherapy, based on analysis of short-term responses.
引用
收藏
页码:309 / 320
页数:12
相关论文
共 50 条
  • [21] SOFT-TISSUE SARCOMAS - THE ROLE OF RADIATION-THERAPY
    SUIT, HD
    HOSPITAL PRACTICE, 1982, 17 (07): : 114 - 120
  • [22] Prognosis of Radiation Associated Bone and Soft-tissue Sarcomas
    Chen, Y.
    Calkins, G.
    Hornicek, F.
    Harmon, D.
    Giraud, C.
    Nielsen, G.
    Meltzer, P.
    Suit, H.
    Michaelson, J.
    DeLaney, T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S138 - S138
  • [23] Results of radiation therapy for unresected soft-tissue sarcomas
    Kepka, L
    DeLaney, TF
    Suit, HD
    Goldberg, SI
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (03): : 852 - 859
  • [24] Radiation Therapy for Soft-Tissue Sarcomas: A Primer for Radiologists
    Wortman, Jeremy R.
    Tirumani, Harsha
    Jagannathan, Jyothi P.
    Rosenthal, Michael H.
    Shinagare, Atul B.
    Hornick, Jason L.
    Baldini, Elizabeth H.
    Ramaiya, Nikhil H.
    RADIOGRAPHICS, 2016, 36 (02) : 554 - 572
  • [25] PREOPERATIVE HYPERTHERMIA AND RADIATION FOR SOFT-TISSUE SARCOMAS - ADVANTAGE OF 2 VS ONE HYPERTHERMIA TREATMENTS PER WEEK
    LEOPOLD, KA
    HARRELSON, J
    PROSNITZ, L
    SAMULSKI, TV
    DEWHIRST, MW
    OLESON, JR
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1989, 16 (01): : 107 - 115
  • [26] PHASE-II TRIAL OF ECHINOMYCIN IN ADVANCED SOFT-TISSUE SARCOMAS - A SOUTHWEST ONCOLOGY GROUP-STUDY
    TAYLOR, SA
    METCH, B
    BALCERZAK, SP
    HANSON, KH
    INVESTIGATIONAL NEW DRUGS, 1990, 8 (04) : 381 - 383
  • [27] PHASE-II STUDY OF MITOXANTRONE IN UNTREATED AND PREVIOUSLY MINIMALLY TREATED PATIENTS WITH METASTATIC SOFT-TISSUE SARCOMAS
    QUIRT, I
    EISENHAUER, E
    BRAMWELL, V
    KNOWLING, M
    GRAFTON, C
    HIRTE, W
    CRIPPS, M
    MAKSYMIUK, A
    CANCER TREATMENT REPORTS, 1987, 71 (11): : 1109 - 1110
  • [28] Preoperative moderate hypofractionated radiation therapy for soft-tissue sarcomas: response analysis
    Chen-Zhao, X.
    Montero, A.
    de las Heras, J.
    Alvarez, B.
    Barrientos, I.
    Prado, A.
    Ciervide, R.
    Lopez, M.
    Garcia-Aranda, M.
    Ortiz, E.
    Gutierrez, M.
    Sanchez, E.
    Hernando, O.
    De la Casa, M. A.
    Valero, J.
    Alonso, R.
    Fernandez-Leton, P.
    Rubio, C.
    RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S1210 - S1211
  • [29] PHASE-II STUDY OF NIMUSTINE IN METASTATIC SOFT-TISSUE SARCOMA
    WAGENER, DJT
    SOMERS, R
    SANTORO, A
    VERWEIJ, J
    WOLL, PJ
    BLACKLEDGE, G
    SCHUTTE, HJ
    LENTZ, MA
    VANGLABBEKE, M
    EUROPEAN JOURNAL OF CANCER, 1991, 27 (12) : 1604 - 1605
  • [30] PHASE-II STUDY OF EPIRUBICIN IN ADVANCED SOFT-TISSUE SARCOMA
    CHEVALLIER, B
    MONTCUQUET, P
    FACHINI, T
    BUI, BN
    KERBRAT, P
    BASTIT, P
    VAN, MV
    BULLETIN DU CANCER, 1990, 77 (10) : 991 - 995